Sickle Cell Disease

ASH recognized three Choosing Wisely Champions during the ASH Annual Meeting and Exposition, held last month in Atlanta.

The American Red Cross has declared, for the first time, a national blood crisis.

In this video, Matthew M. Heeney, MD, highlighted “interesting” real-world and long-term follow-up studies for the treatment of sickle cell that were presented at ASH Annual Meeting and Exposition.

The FDA granted accelerated approval to voxelotor tablets for the treatment children aged 4 to 11 years with sickle cell disease.

The diligence and awareness to stay home demonstrated by patients with sickle cell disease during the COVID-19 pandemic proved crucial in reducing morbidity and mortality, according to a study presented at ASH Annual Meeting and Exposition.

New guidelines for sickle cell disease issued by ASH and published in Blood Advances aim to inform practitioners and patients on use of hematopoietic stem cell transplantation in clinical practice.

The CRISPR/Cas9 gene-editing system is producing results that may transform the treatment of certain diseases, according to Nobel Prize winner Jennifer A. Doudna, PhD.

The FDA granted priority review to voxelotor for the treatment of children aged 4 to 11 years with sickle cell disease.

Sickle cell disease is the most common genetic disorder, affecting approximately 100,000 people in the United States.

Individuals with sickle cell disease or trait demonstrated a higher risk for COVID-19 hospitalization and death than individuals without these conditions, according to study findings published in Annals of Internal Medicine.